ADXS Stock Overview
A clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Ayala Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.027 |
| 52 Week High | US$1.49 |
| 52 Week Low | US$0.0012 |
| Beta | 0 |
| 11 Month Change | -0.37% |
| 3 Month Change | 35.00% |
| 1 Year Change | -96.63% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -97.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| ADXS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | 1.0% |
| 1Y | -96.6% | 15.6% | 31.4% |
Return vs Industry: ADXS underperformed the US Biotechs industry which returned 15.6% over the past year.
Return vs Market: ADXS underperformed the US Market which returned 30.7% over the past year.
Price Volatility
| ADXS volatility | |
|---|---|
| ADXS Average Weekly Movement | 233.7% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ADXS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ADXS's weekly volatility has decreased from 264% to 234% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 21 | Ken Berlin | www.ayalapharma.com |
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company’s lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
Ayala Pharmaceuticals, Inc. Fundamentals Summary
| ADXS fundamental statistics | |
|---|---|
| Market cap | US$1.33m |
| Earnings (TTM) | -US$48.07m |
| Revenue (TTM) | US$13.00k |
102.4x
P/S Ratio0.0x
P/E RatioIs ADXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADXS income statement (TTM) | |
|---|---|
| Revenue | US$13.00k |
| Cost of Revenue | US$13.00k |
| Gross Profit | US$0 |
| Other Expenses | US$48.07m |
| Earnings | -US$48.07m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.98 |
| Gross Margin | 0% |
| Net Profit Margin | -369,784.62% |
| Debt/Equity Ratio | -33.3% |
How did ADXS perform over the long term?
See historical performance and comparison